Mersana Therapeutics earning call
MRSN Stock , This is the first quarter 2020 Mersana’s conference call. We released a press release this morning that reviewed our first quarter 2020 results as well as business updates. These will be discussed on the call. The replay of the call today will be accessible on our Investors & Media section of our website.
Following our prepared remarks, we’ll then start the call for Q&A. Before we get started I’d like you to know that our call may contain forward-looking statements as defined by the of the federal securities laws. These are not historical fact and are based on the management’s views and assumptions as well as on current information available. These statements are subject to risk as well as uncertainties which could lead actual results and the execution of the plans of the company to differ significantly, including the risk that early promising preclinical data for XMT-1536 and XMT-1592. They are not indicative of the outcomes of the ongoing or future research programs or clinical studies in the sense that the creation and identification of our company’s candidate products and the development of new platforms could take longer or cost more than anticipated, and our clinical trials may not be completed in the timeframe we have set in the event that they are completed they ever happen. These risks are addressed within the firm’s SEC filings, which include, not limited to the annual report of the company on Form 10-K , filed the 28th of February, 2020 and the subsequent filings.
Furthermore, while we anticipate that the COVID-19 pandemic could affect the company’s research and clinical research efforts, operations and financial performance however, the degree of effect on the operations of the company as well as the value and the market for the company’s stock will be contingent on events that will occur in the future, which are uncertain and are not able to be forecast without certainty at the moment including the ultimate time frame of the pandemic restrictions on travel, quarantines physical distancing, and closure obligations in U.S. and in other nations, and the efficacy of the global efforts to combat and contain the illness. In addition, unless legally required the company does not assume any obligation to make any changes to the forward-looking statements in a public forum regardless of any new information that is made available in the near future. After that, I’ll transfer the call to Anna Protopapas, Mersana’s president and chief executive chief executive officer.
Mersana Therapeutics Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| MRSN | +56.91% | -53.31% | -14.13% | -52% |
| S&P | -7.62% | +49.76% | +8.40% | +69% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $184.08M | -4.0% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $34.14M | +101.1% |
| Short Term Debt | $2.70M | +20.6% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -78.2% | +32.5% |
| Return On Invested Capital | -192.7% | +8.1% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | $54.83M | – |
| Operating Free Cash Flow | $55.26M | – |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 2.87 | 2.42 | 2.86 | 4.90 | +42.3% |
| Price to Sales | 10,167.10 | 154.14 | 69.76 | 55.45 | -99.6% |
| Price to Tangible Book Value | 2.87 | 2.42 | 2.86 | 4.90 | +42.3% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -6.45 | -2.73 | -4.94 | -6.85 | -38.7% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -97.2% | -107.9% | -117.7% | -169.5% | +131.1% |
| Total Debt | $38.86M | $37.67M | $37.43M | $36.84M | +91.7% |
